Literature DB >> 6460691

Role of individual chains of HLA-DR antigens in activation of T cells induced by alloantigens.

R Palacios.   

Abstract

The role of HLA-DR antigens in the activation of T cells in the allogeneic mixed lymphocyte reaction (MLR) was studied by using antibodies raised against the alpha, beta or the complex of both chains of the HLA-DR antigens. Antisera directed against the alpha or the beta chain strongly inhibited the T-cell proliferative response when added at the beginning of MLR cultures but not 72 h later. T cells from MLR cultures treated with either alpha-chain- or beta-chain-specific antibodies did not respond to interleukin-2 (IL-2) by proliferating, whereas T cells from non-anti-DR-treated cultures showed a proliferative response to IL-2-stimulation. However, neither the anti-alpha chain nor the anti-beta chain serum was able to inhibit continuous proliferation of already activated, IL-2-reactive T cells supported by IL-2. In MLR, OKT4+ but not OKT8+ lymphocytes synthesized IL-2. This function was abrogated by the alpha-chain-specific antibody but not by the anti-beta chain serum. Interleukin-1 (IL-1) did not reverse the inhibitory activity on IL-2 synthesis of the alpha-chain antibody, while IL-1 promoted the production of IL-2 in MLR cultures not exposed to the anti-DR sera. In addition, nonstimulated OKT4+ cells were unresponsive to IL-1 and did not produce IL-2. From these results, it is concluded that HLA-DR antigens participate actively in the activation of T cells by allogeneic non-T cells. Thus, both the alpha and beta chains of HLA-DR antigens render resting T cells sensitive to IL-2. In addition, the alpha but not the beta chain participates in the production of IL-2 by enabling OKT4+ lymphocytes to respond to IL-1 and subsequently to synthesize IL-2. Once T cells have acquired responsiveness to IL-2 and this growth factor has been produced there is no further requirement for HLA-DR antigens. Continuous proliferation and growth of IL-2-reactive T cells depends on the availability of interleukin-2.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6460691     DOI: 10.1007/bf00342200

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  31 in total

1.  Specificity and suppressor function of human T cells responsive to autologous non-T cells.

Authors:  T Sakane; I Green
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

2.  Production of monoclonal antibodies reacting with peripheral blood mononuclear cell surface differentiation antigens.

Authors:  G S Eisenbarth; B F Haynes; J A Schroer; A S Fauci
Journal:  J Immunol       Date:  1980-03       Impact factor: 5.422

3.  Antiserum inhibition of the mixed lymphocyte culture (MLC) interaction. Inhibitory effect of antibodies reactive with HLA-D-associated determinants.

Authors:  D Albrechtsen; B G Solheim; E Thorsey
Journal:  Cell Immunol       Date:  1977-02       Impact factor: 4.868

4.  Role of the autologous rosette-forming T cells in the concanavalin A-induced suppressor cell function.

Authors:  R Palacios
Journal:  Cell Immunol       Date:  1981-07-01       Impact factor: 4.868

5.  HLA-DR antigens render resting T cells sensitive to interleukin-2 and induce production of the growth factor in the autologous mixed lymphocyte reaction.

Authors:  R Palacios; G Möller
Journal:  Cell Immunol       Date:  1981-09-01       Impact factor: 4.868

6.  Characterization of HLA-D-region antigens by two-dimensional gel electrophoresis. Molecular-genotyping.

Authors:  D J Charron; H O McDevitt
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

7.  Binding of purified, soluble major histocompatibility complex polypeptide chains onto isolated T-cell receptors. I. Reactivity against allo- and self-determinants.

Authors:  H Binz; H Frischknecht; C Mercolli; S Dunst; H Wigzell
Journal:  J Exp Med       Date:  1979-11-01       Impact factor: 14.307

8.  Human postthymic precursor cells in health and disease. II. Their loss and dysfunction in systemic lupus erythematosus and their partial correction with serum thymic factor.

Authors:  R Palacios; D Alarcón-Segovia; L Llorente; A Ruíz-Arguelles; E Díaz-Jouanen
Journal:  J Clin Lab Immunol       Date:  1981-03

9.  Two distinct factors are required for induction of T-cell growth.

Authors:  E L Larsson; N N Iscove; A Coutinho
Journal:  Nature       Date:  1980-02-14       Impact factor: 49.962

10.  The mouse-primed lymphocyte typing test. III. Dissociation of T lymphocyte-stimulating determinants and antibody-defined specificities of the I region-associated Ia antigens.

Authors:  A B Peck; J Klein; H Wigzell
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

View more
  6 in total

1.  A defect in immunoregulatory synovial fluid T cells in Behçet's syndrome.

Authors:  J Alcocer-Varela; A Laffon; C Abud-Mendoza; D Alarcon-Segovia
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

2.  Production and characterization of monoclonal antibodies recognizing the alpha-chain subunits of human ia alloantigens.

Authors:  T E Adams; J G Bodmer; W F Bodmer
Journal:  Immunology       Date:  1983-12       Impact factor: 7.397

3.  The alpha chain, not the beta chain of HLA-DR antigens participates in activation of T cells in autologous mixed lymphocyte reaction.

Authors:  R Palacios; L Claesson; G Möller; P A Peterson; E Möller
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

4.  Human pregnancy serum inhibits interleukin-2 production.

Authors:  N S Nicholas; G S Panayi; A M Nouri
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

5.  HLA-DR antigens induce proliferation and cytotoxicity of T cells against haptenated (TNP and FITC) self structures.

Authors:  R Palacios; G Möller; L Claesson; P A Peterson
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

6.  Autologous mixed lymphocyte reaction in man. XIII. Characterization of the T-T autologous mixed lymphocyte reaction.

Authors:  S Gupta; G Chandy; M Thornton; M Goldberg
Journal:  J Clin Immunol       Date:  1985-05       Impact factor: 8.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.